Westchester Medical Center ...

Dr. Mark D. Hurwitz

Claim this profile

Westchester Medical Center

Studies Prostate Adenocarcinoma
Studies Prostate Cancer
6 reported clinical trials
21 drugs studied

Affiliated Hospitals

Image of trial facility.
Westchester Medical Center
Image of trial facility.
Thomas Jefferson University Hospital

Clinical Trials Mark D. Hurwitz is currently running

Image of trial facility.

Shorter vs Usual Radiation Therapy

for Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Recruiting2 awards Phase 310 criteria
Image of trial facility.

Apalutamide + Targeted Radiation

for Prostate Cancer

This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting2 awards Phase 3

More about Mark D. Hurwitz

Clinical Trial Related4 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Mark D. Hurwitz has experience with
  • Flutamide
  • External Beam Radiation Therapy
  • Apalutamide
  • Bicalutamide
  • Buserelin
  • Degarelix

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Mark D. Hurwitz specialize in?
Is Mark D. Hurwitz currently recruiting for clinical trials?
Are there any treatments that Mark D. Hurwitz has studied deeply?
What is the best way to schedule an appointment with Mark D. Hurwitz?
What is the office address of Mark D. Hurwitz?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security